UK Markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
204.73-5.44 (-2.59%)
At close: 04:00PM EST
204.65 -0.08 (-0.04%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close210.17
Open204.01
Bid204.00 x 1100
Ask204.70 x 800
Day's range200.08 - 212.74
52-week range117.34 - 497.49
Volume10,167,546
Avg. volume11,557,452
Market cap83.008B
Beta (5Y monthly)1.34
PE ratio (TTM)12.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    2 Top Biotech Stocks to Buy and Hold for 10 Years

    With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN). Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market.

  • Motley Fool

    Is Moderna Stock Too Expensive in 2022?

    Moderna (NASDAQ: MRNA) stock has soared for the past two years thanks to its leadership in the coronavirus vaccine market. Then, they doubled down on their positions when Moderna commercialized its product and started to generate billions of dollars in revenue and profit. Considering this point, is Moderna stock too expensive?

  • Motley Fool

    When Will Moderna Stock Be a Screaming Buy?

    Moderna (NASDAQ: MRNA) is now far below its peak market cap last summer of nearly $200 billion. In this Motley Fool Live video recorded on Jan. 5, Fool contributors Keith Speights and Brian Orelli discuss how low Moderna needs to go to make the stock a clear bargain. Keith Speights: Now, another company has already been a huge winner with COVID-19 and I'm talking about Moderna.